227 related articles for article (PubMed ID: 35714862)
1. Inflammatory and Noninflammatory Thyroid Eye Disease: Comparison of Disease Signs, Symptoms, and Quality of Life in Patients in the United States.
Wang Y; Padnick-Silver L; Francis-Sedlak M; Holt RJ; Foley C; Douglas RS
Endocr Pract; 2022 Sep; 28(9):842-846. PubMed ID: 35714862
[TBL] [Abstract][Full Text] [Related]
2. Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States.
Cockerham KP; Padnick-Silver L; Stuertz N; Francis-Sedlak M; Holt RJ
Ophthalmol Ther; 2021 Dec; 10(4):975-987. PubMed ID: 34478126
[TBL] [Abstract][Full Text] [Related]
3. Physician-Perceived Impact of Thyroid Eye Disease on Patient Quality of Life in the United States.
Wang Y; Sharma A; Padnick-Silver L; Francis-Sedlak M; Holt RJ; Foley C; Massry G; Douglas RS
Ophthalmol Ther; 2021 Mar; 10(1):75-87. PubMed ID: 33196932
[TBL] [Abstract][Full Text] [Related]
4. How patients experience thyroid eye disease.
Smith TJ; Hegedüs L; Lesser I; Perros P; Dorris K; Kinrade M; Troy-Ott P; Wuerth L; Nori M
Front Endocrinol (Lausanne); 2023; 14():1283374. PubMed ID: 38027128
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of thyroid eye disease: quality-of-life questionnaire (TED-QOL) in Korean patients.
Son BJ; Lee SY; Yoon JS
Can J Ophthalmol; 2014 Apr; 49(2):167-73. PubMed ID: 24767223
[TBL] [Abstract][Full Text] [Related]
6. Teprotumumab for the treatment of thyroid eye disease.
Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
8. Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values.
Smith TJ; Cockerham K; Barretto N; Hirst A; Oliver L; Enstone A; Brandolini G; Taylor SD; Holt RJ
Endocr Pract; 2024 May; 30(5):470-475. PubMed ID: 38341128
[TBL] [Abstract][Full Text] [Related]
9. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
Thyroid; 2024 Jun; ():. PubMed ID: 38824618
[No Abstract] [Full Text] [Related]
11. Characteristics of Diabetic and Nondiabetic Patients With Thyroid Eye Disease in the United States: A Claims-Based Analysis.
Patel VK; Padnick-Silver L; D'Souza S; Bhattacharya RK; Francis-Sedlak M; Holt RJ
Endocr Pract; 2022 Feb; 28(2):159-164. PubMed ID: 34781042
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of orbital soft tissue biomechanical parameters in patients with thyroid eye disease using the non-contact Corvis ST.
Moeen Rad A; Zarei-Ghanavati S; Sabermoghaddam A; Ghavami Shahri SH; Bakhtiari E; Kiarudi MY
Int Ophthalmol; 2023 Oct; 43(10):3615-3621. PubMed ID: 37393605
[TBL] [Abstract][Full Text] [Related]
13. Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States.
Smith TJ; Cockerham K; Lelli G; Choudhary C; Taylor S; Barretto N; Enstone A; Oliver L; Lynch J; Holt RJ
JAMA Ophthalmol; 2023 Feb; 141(2):159-166. PubMed ID: 36580313
[TBL] [Abstract][Full Text] [Related]
14. Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.
Yu CY; Ford RL; Wester ST; Shriver EM
Indian J Ophthalmol; 2022 Jul; 70(7):2335-2345. PubMed ID: 35791115
[TBL] [Abstract][Full Text] [Related]
15. Asymmetric proptosis in thyroid eye disease.
Rana K; Garg D; Yong LSS; Leyden J; Patel S; Slattery J; Davis G; Chan WO; Selva D
Int Ophthalmol; 2024 Apr; 44(1):206. PubMed ID: 38678129
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease.
Subramanian PS; Cho RI; Kahana A
Curr Opin Ophthalmol; 2023 Nov; 34(6):487-492. PubMed ID: 37610428
[TBL] [Abstract][Full Text] [Related]
17. Advances in the Treatment of Thyroid Eye Disease Associated Extraocular Muscle Myopathy and Optic Neuropathy.
Lu TJ; Amarikwa L; Sears CM; Kossler AL
Curr Neurol Neurosci Rep; 2022 Jun; 22(6):313-325. PubMed ID: 35614367
[TBL] [Abstract][Full Text] [Related]
18. [Monoclonal antibodies in the treatment of thyroid eye disease].
Cheredanova VR; Poteshkin YE
Vestn Oftalmol; 2021; 137(4):116-122. PubMed ID: 34410066
[TBL] [Abstract][Full Text] [Related]
19. Clinical profile of 80-year-old and older thyroid eye disease patients.
Levy N; Leiba H; Landau K; Zloto O; Huna-Baron R
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2727-2736. PubMed ID: 35338398
[TBL] [Abstract][Full Text] [Related]
20. The "Quiet TED"-A Special Subgroup of Thyroid Eye Disease.
Iñiguez-Ariza NM; Sharma A; Garrity JA; Stan MN
Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):551-555. PubMed ID: 33782324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
